Navigation Links
Initiation of Lantus® Leads to Better Glycemic Control at Similar Weight Gain Versus Other Comparators in Patients With Type 2 Diabetes
Date:9/12/2011

cs, therapies, services, and devices. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes. Investigational compounds in the pipeline include an injectable GLP-1 agonist being studied as a single agent, in combination with basal insulins, and/or in combination with oral antidiabetic agents.

About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by,
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
2. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
3. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
4. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
5. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
6. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
7. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
8. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
9. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
10. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
11. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... and HENDERSONVILLE, N.C. , ... bidding procurement program for home medical equipment is ... North Carolina to lay off employees or ... quality of service and products received by Medicare beneficiaries, ... the defective and dangerous program, the Centers for ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
... IRVINE, Calif., Nov. 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion ... device company, today announced a multi-year technology licensing ... capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 3CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 4
(Date:5/21/2013)... Human Reproduction & Embryology) is now the world,s leading ... expected this year, presenting a wealth of new research ... public interest. Reports from proceedings of the ESHRE congress ... , This year,s event will be held at the ... July. , The scientific programme for this year,s event ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud and ... the featured company in an impact report written and ... Bets on Converged Cloud Integration and Process-Orchestration Suites,” offers ... pricing, customers and competition. , “For organizations ... and process orchestration, especially when price, ease of use ...
(Date:5/21/2013)... risk of sudden infant death syndrome (SIDS) is five ... new study finds. British researchers noted that bed-sharing ... not drink, use illegal drugs or smoke. They advised ... of infant death in developed countries, would drop dramatically ... In the United States, all parents are advised to ...
(Date:5/21/2013)... gold nanoparticles are usually toxic to cells, but ... Mayo Clinic researchers found out why, and determined ... cancer cells. The discovery is detailed in the ... Biological Chemistry ., "This study identifies a novel ... the cell death or apoptosis which should occur ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have ... that Dr. David Sherberg, DMD, has joined Coast Dental ... Sherberg provides preventive, restorative and cosmetic dentistry to patients ... team provide a wide variety of services ... therapy, crowns, bridges, dentures, dental implant restorations, veneers, laser ...
Breaking Medicine News(10 mins):Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3
... rapid spread and growing variety of unregulated tobacco products, ... and broader regulation // to prevent more than five ... ,The agency also called for anti-tobacco programmes, especially aimed ... was apparently increasing. ,Tobacco use, it finds, also ...
... to computerize NHS with ?20 billion is becoming late than scheduled by about two ... records electronically for 50 million NHS patients, but this will not still be started ... programme for IT (NPfIT) really costs more than three times than the previously said ... ...
... P J Abdul Kalam today met representatives of the ... impasse with the students and doctors deciding// to continue ... medicos, which also included members of AIIMS Faculty Association ... 45-minute meeting with Kalam. The medicos presented a charter ...
... research that showed that high fat in the diet ... a high fat intake is even beneficial// and protective ... Granger and colleagues from the Menzies Research Institute in ... in Melbourne studied 652 people who had been diagnosed ...
... strokes in young people, though the condition's progress can be ... ,The disorder known as Fabry disease is characterised by attacks ... skin lesions and progressive renal insufficiency. ,It is ... body to process oils, waxes and fatty acids, reports the ...
... makes the condition worse and it is in a position ... profession// to makeup the shortfall. Most strugglers were the remote ... rise in female part-time GPs, more workloads and immence retirement ... such hardest shortage’. ,Dr Brian McKinstry, a ...
Cached Medicine News:Health News:President Kalam Meets Striking Medicos However Stir to Continue 2Health News:Rare Genetic Disorder Could Cause Strokes In Young People 2Health News:Scotland Faces Shortage Of GPs 2
... comfortable eye protection Properly manufactured radiation ... scatter radiation. Our high quality frames and ... with minimized weight. Our lenses are made ... meet all industry standards. Most Pulse Glasses ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
Medicine Products: